Back to Search

Ocrelizumab Treatment for Multiple Sclerosis

A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)

Recruiting Observational Study
Multiple Sclerosis
More trials: Multiple Sclerosis clinical trials
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
842 (estimated)
Sponsor
Hoffmann-La Roche · Industry
Who this trial is looking for

This trial is looking for people with Multiple Sclerosis to see how they feel about treatment with ocrelizumab after one year. Participants will answer questions about their satisfaction with the therapy.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have been diagnosed with Multiple Sclerosis.
  • I am receiving my first treatment with ocrelizumab.

You may not be able to join if

  • I am participating in other studies for MS treatments.
  • I have taken rituximab or ublituximab before.
  • I have severe psychiatric disability.
  • I am pregnant.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

The main purpose of the study is to evaluate participant satisfaction after administration of ocrelizumab subcutaneously (SC) after 12 months using the therapy administration satisfaction questionnaire subcutaneous (TASQ-SC).

Trial Locations

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Diagnosis of MS * RMS and PPMS participants diagnosed according to the McDonald criteria of 2017 or revised McDonald criteria 2024 * First treatment during the course of MS therapy with ocrelizumab SC according to the local prescribing information, regardless of the reason for…
Contacts

Reference Study ID Number: ML45551 https://forpatients.roche.com/ No attachments to email below

888-662-6728 (U.S. Only)

global-roche-genentech-trials@gene.com

CONTACT

Fastest response: use the inquiry form https://www.gene.com/contact-us/submit-medical-inquiry

CONTACT

NCT ID: NCT06780150 Source: ClinicalTrials.gov